MassBio® Welcomes Leyton to its Expansive List of Edge Preferred Partners

Sep 28, 2021

The international firm will be the program’s sole tax credit and audit consultancy

September 28, 2021 (CAMBRIDGE, MA) – The Massachusetts Biotechnology Council (MassBio®) today announced that Leyton, the global consultancy with expertise in tax credits, has joined MassBio Edge as a Preferred Partner. By aggregating the purchasing power of the 1,400+ member companies within MassBio, MassBio Edge allows members to have a strong presence in the marketplace and benefit from competitive discounts and premier customer service, which saves members more than $200 million each year.

Founded in 1997, Leyton has leveraged its 24 years of experience to bring its life sciences clientele underutilized tax credits available to the industry. Leyton uses a dual-approach methodology, with both tax professionals and bio-technical specialists, and works with companies one-on-one to deliver customized solutions for each client. On average, Leyton’s experienced team finds 40% more tax credits than leading firms because of their expertise in helping companies understand and document their qualifying projects.

“The Massachusetts life sciences cluster is largely comprised of small and emerging biotechs which are often pre-clinical and pre-revenue and working to address some of the world’s greatest unmet medical needs,” said Jason Cordeiro, Vice President of Business Operations, MassBio. “We are proud to welcome Leyton to our leading MassBio Edge program to support the growth of this cohort and ensure the entire ecosystem of companies that make up our cluster have all the resources possible to invest in research and development.”

With its United States headquarters located in Boston, Leyton has a unique understanding of the Massachusetts life sciences cluster and its consistent growth over the last 15 years. With highly educated engineers and scientists on staff and integrated within the company’s methodology, Leyton makes sure no dollars are left unclaimed.

“Massachusetts is the fastest growing life sciences hub and we are thrilled to partner with MassBio and support the continued growth of the industry here,” said Tom McDanell, SVP, Leyton USA. “In the last year, Leyton has helped source $1.5 billion to help companies reinvest in their business, and we look forward to bringing our expertise to MassBio’s membership so they can focus on improving patient lives.”

“I am confident that Leyton’s knowledge and expertise will allow life sciences companies in Massachusetts and beyond to prioritize innovation so they can continue to develop breakthrough treatments and therapies,” said Maggie Crowley, Head of Strategic Development, Leyton USA. “We’re changing the way that the life sciences industry navigates the tax credit landscape, and our scientists and tax professionals are primed to work with MassBio’s members and make sure nothing gets overlooked.”

For more information about Leyton and to view contract highlights, please visit the MassBio Edge website.

See all MassBio News